https://www.selleckchem.com/products/3-typ.html
We also showed that liraglutide significantly decreased serum triglyceride levels, also driven by the observed reduction in patients with type 2 diabetes, however it did not significantly affect the rest lipid parameters. Liraglutide was associated with increased incidence of gastrointestinal adverse events, while, no other safety issues were identified. Our results do not substantiate the use of liraglutide in patients with NAFLD yet, despite its promising role. Our results do not substantiate the use of liraglutide in patients with NAFL
Like
Comment
Share
